Actively Recruiting
CXCL9 and EASIX for Prediction of Acute Graft Versus Host Disease
Led by Henry Ford Health System · Updated on 2026-05-01
100
Participants Needed
1
Research Sites
242 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The prediction of severe acute GVHD before it occurs is of high importance for ensuing clinical decisions and overall success of allogeneic SCT. The key immunologic signatures associated with clinical outcomes after different graft versus host disease prophylaxis methods or peripheral blood stem cell transplant are largely unknown.
CONDITIONS
Official Title
CXCL9 and EASIX for Prediction of Acute Graft Versus Host Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients older than 18 years admitted for allogeneic stem cell transplant using peripheral blood for malignant disease.
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Henry Ford Health System
Detroit, Michigan, United States, 48202
Actively Recruiting
Research Team
S
shatha farhan, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here